TargetMol

JNJ-26489112

Product Code:
 
TAR-T27672
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27672-100mg100mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27672-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
JNJ-26489112 is a drug potentially for the treatment of depression and photosensitive epilepsy.
CAS:
871824-55-4
Formula:
C9H11ClN2O4S
Molecular Weight:
278.71
Purity:
0.98
SMILES:
NS(=O)(=O)NC[C@H]1COc2cc(Cl)ccc2O1

Documents

References

1. McComsey DF, Smith-Swintosky VL, Parker MH, Brenneman DE, Malatynska E, White HS, Klein BD, Wilcox KS, Milewski ME, Herb M, Finley MF, Liu Y, Lubin ML, Qin N, Reitz AB, Maryanoff BE. Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112). J Med Chem. 2013 Nov 27;56(22):9019-30. doi: 10.1021/jm400894u. PubMed PMID: 24205976; PubMed Central PMCID: PMC4004761. 2. Di Prospero NA, Gambale JJ, Pandina G, Ford L, Girgis S, Moyer JA, Xi L, Nye JS, Kasteleijn-Nolst Trenit? D. Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study. Epilepsy Res. 2014 May;108(4):709-16. doi: 10.1016/j.eplepsyres.2014.01.018. PubMed PMID: 24560845. 3. Eichenbaum G, Zhou J, Kelley MF, Roosen W, Costa-Giomi P, Louden C, Di Prospero NA, Pandina G, Singh JB, Ford L, Moyer JA, Nork TM, Ver Hoeve JN, Aguirre GD. Implications of retinal effects observed in chronic toxicity studies on the clinical development of a CNS-active drug candidate. Regul Toxicol Pharmacol. 2014 Jul;69(2):187-200. doi: 10.1016/j.yrtph.2014.03.005. PubMed PMID: 24680767. 4. Zaccara G, Schmidt D. Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development. Pharmacol Res. 2016 Feb;104:38-48. doi: 10.1016/j.phrs.2015.12.011. Review. PubMed PMID: 26689774.